Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Overview

The purpose of this study is to estimate the relative bioavailability (rBA) of nirmatrelvir/ritonavir oral powder in 3 different food vehicles relative to the Paxlovid® tablets under fasted condition in healthy adult participants, and to estimate the effect of food on the rBA of the nirmatrelvir/ritonavir oral powder formulation. The study will also assess the safety, tolerability, and palatability of nirmatrelvir/ritonavir oral powder in healthy adult participants.

Full Title of Study: “A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF NIRMATRELVIR (PF-07321332) /RITONAVIR ORAL POWDER IN 3 DIFFERENT FOOD DELIVERY VEHICLES RELATIVE TO THE NIRMATRELVIR (PF-07321332) /RITONAVIR COMMERCIAL TABLETS UNDER FASTED CONDITIONS, AND THE EFFECT OF FOOD ON RELATIVE BIOAVAILABILITY OF NIRMATRELVIR (PF-07321332) /RITONAVIR ORAL POWDER IN HEALTHY ADULT PARTICIPANTS”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 29, 2022

Interventions

  • Drug: Nirmatrelvir/ ritonavir
    • Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
  • Drug: Nirmatrelvir/Ritonavir
    • Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
  • Drug: Nirmatrelvir/Ritonavir
    • Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
  • Drug: Nirmatrelvir/ritonavir
    • Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
  • Drug: Nirmatrelvir/ritonavir
    • Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition

Arms, Groups and Cohorts

  • Active Comparator: Treatment A: Nirmatrelvir/ritonavir
    • Nirmatrelvir and ritonavir tablets
  • Experimental: Treatment B: Nirmatrelvir/ ritonavir
    • Nirmatrelvir/ritonavir with water
  • Experimental: Treatment C: Nirmatrelvir/ ritonavir
    • Nirmatrelvir/ ritonavir with infant formula
  • Experimental: Treatment D: Nirmatrelvir/ ritonavir
    • Nirmatrelvir/ ritonavir with vanilla pudding
  • Experimental: Treatment E: Nirmatrelvir/ ritonavir
    • Nirmatrelvir/ ritonavir with food and vanilla pudding

Clinical Trial Outcome Measures

Primary Measures

  • Area under curve from time zero to 72 hours post dose
    • Time Frame: 0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours
  • Peak plasma concentration (Cmax)
    • Time Frame: 0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours

Secondary Measures

  • Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
    • Time Frame: Baseline (Day 0) up to 28 days after last dose of study medication
  • Number of Participants With Notable Electrocardiogram (ECG) Values
    • Time Frame: Baseline (Day 0) up to day 4 of treatment period 5
  • Number of Participants With Clinically Notable Vital Signs
    • Time Frame: Baseline (Day 0) up to day 4 of treatment period 5
  • Number of Participants With Clinically Notable Changes in Clinical laboratory
    • Time Frame: Baseline (Day 0) up to day 4 of treatment period 5
  • Number of Participants With Clinically Notable Abnormality in physical examination
    • Time Frame: Baseline (Day 0) up to day 4 of treatment period 5
  • Palatability assessment of nirmatrelvir/ritonavir oral powder mixed with water/infant formula/vanilla pudding
    • Time Frame: 1, 5, 10 and 20 minutes
  • Area under curve from time zero to 72 hours post dose
    • Time Frame: 0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours
  • Peak plasma concentration (Cmax)
    • Time Frame: 0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours

Participating in This Clinical Trial

Inclusion Criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination (PE), laboratory tests, vital signs and standard 12 lead ECGs. – Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb). – Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures Exclusion Criteria:

  • Positive test result for SARS-CoV-2 infection at the time of Screening or Day -1. – Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). – Clinically relevant abnormalities requiring treatment (eg, acute myocardial infarction, unstable ischemic conditions, evidence of ventricular dysfunction, serious tachy or brady arrhythmias) or indicating serious underlying heart disease (eg, prolonged PR interval, cardiomyopathy, heart failure greater than New York Heart Association (NYHA) 1, underlying structural heart disease, Wolff Parkinson-White syndrome). – Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy). – History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis B surface antibody (HCVAb). Hepatitis B vaccination is allowed. – Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention. – Participant who have received a COVID-19 vaccine within 7 days before screening or admission, or who are to be vaccinated with a COVID-19 vaccine at any time during the study confinement period. – A positive urine drug test.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Pfizer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pfizer CT.gov Call Center, Study Director, Pfizer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.